Trial · NCT02600494
Participant flow21
How many started, completed or left each group, period by period.
1 to 20 of 21
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part A (6 Week Double-Blind Treatment) | STARTED | Lumateperone 28 mg (ITI-007 40 mg Tosylate) | 183 | |
| Part A (6 Week Double-Blind Treatment) | STARTED | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 185 | |
| Part A (6 Week Double-Blind Treatment) | STARTED | Placebo | 186 | |
| Part A (6 Week Double-Blind Treatment) | Number of Patients Randomized and Took at Least 1 Dose of Study Drug | Lumateperone 28 mg (ITI-007 40 mg Tosylate) | 180 | |
| Part A (6 Week Double-Blind Treatment) | Number of Patients Randomized and Took at Least 1 Dose of Study Drug | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 184 | |
| Part A (6 Week Double-Blind Treatment) | Number of Patients Randomized and Took at Least 1 Dose of Study Drug | Placebo | 185 | |
| Part A (6 Week Double-Blind Treatment) | COMPLETED | Lumateperone 28 mg (ITI-007 40 mg Tosylate) | 126 | |
| Part A (6 Week Double-Blind Treatment) | COMPLETED | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 113 | |
| Part A (6 Week Double-Blind Treatment) | COMPLETED | Placebo | 138 | |
| Part A (6 Week Double-Blind Treatment) | NOT COMPLETED | Lumateperone 28 mg (ITI-007 40 mg Tosylate) | 57 | |
| Part A (6 Week Double-Blind Treatment) | NOT COMPLETED | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 72 | |
| Part A (6 Week Double-Blind Treatment) | NOT COMPLETED | Placebo | 48 | |
| Part B (6 Month Open-Label Treatment) | STARTED | Lumateperone 28 mg (ITI-007 40 mg Tosylate) | 0 | |
| Part B (6 Month Open-Label Treatment) | STARTED | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 127 | |
| Part B (6 Month Open-Label Treatment) | STARTED | Placebo | 0 | |
| Part B (6 Month Open-Label Treatment) | COMPLETED | Lumateperone 28 mg (ITI-007 40 mg Tosylate) | 0 | |
| Part B (6 Month Open-Label Treatment) | COMPLETED | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 74 | |
| Part B (6 Month Open-Label Treatment) | COMPLETED | Placebo | 0 | |
| Part B (6 Month Open-Label Treatment) | NOT COMPLETED | Lumateperone 28 mg (ITI-007 40 mg Tosylate) | 0 | |
| Part B (6 Month Open-Label Treatment) | NOT COMPLETED | Lumateperone 42 mg (ITI-007 60 mg Tosylate) | 53 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02600494/flow